SPY319.34+7.98 2.56%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%
News
AKBA
--
0.00%
--
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 72,000 shares of Akebia's common stock on M
PR Newswire · 4d ago
Edited Transcript of AKBA earnings conference call or presentation 10-Mar-20 1:00pm GMT
Q4 2019 Akebia Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents · 4d ago
Akebia Therapeutics: A Clear Path To A Blockbuster CKD-Anemia Treatment
Seeking Alpha - Article · 5d ago
Edited Transcript of AKBA earnings conference call or presentation 5-May-20 12:30pm GMT
Q1 2020 Akebia Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents · 05/27 02:15
Akebia Therapeutics to Present at Jefferies Virtual Global Healthcare Conference
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its President and Chief Executive Officer, John P. Butler, will participate in the Jefferies V
PR Newswire · 05/26 12:00
Akebia Therapeutics Announces Change to Virtual Annual Meeting of Stockholders
PR Newswire · 05/21 21:05
Akebia Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the underwriters of its previously announced public offering, which closed on May 14, 2020, ha
PR Newswire · 05/19 20:05
Akebia announces filing in Japan expanded use of Riona tablets
Seeking Alpha - Article · 05/18 15:24
Akebia Therapeutics Announces Collaboration Partner's Submission of Supplemental New Drug Application for Use of Riona® (ferric citrate hydrate) to Treat Adult Patients with Iron Deficiency Anemia in Japan
PR Newswire · 05/18 13:00
Akebia Therapeutics, Inc. (AKBA) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Akebia Therapeutics, Inc. (AKBA).
Zacks · 05/13 15:37
'This $AKBA short report reads dumb to me, like someone drank too much coffee and got overly stimulated for nothing. But I'm willing to listen to a saner interpretation and change my mind' -Tweet From STAT News' Adam Feuerstein
https://twitter.com/adamfeuerstein/status/1260243844039413760
Benzinga · 05/12 16:23
Akebia Therapeutics Shares Tick Lower Following Tweet From Short Seller Muddy Waters 'Our PRTA short opened our eyes to the...world of misleading presentation of biotech trial data. No view / no position on AKBA, but it does raise similar questions'
https://twitter.com/muddywatersre/status/1260226977677500419
Benzinga · 05/12 15:30
32 Stocks Moving in Tuesday's Pre-Market Session
Gainers
Benzinga · 05/12 11:16
Akebia Therapeutics prices upsized equity offering, shares down 5% after-hours
Akebia Therapeutics (NASDAQ:AKBA) prices upsized public offering of 11M common shares at $12.00 per share, for gross proceeds of $132M (upsized from $100M)
seekingalpha · 05/12 11:06
5 Stocks To Watch For May 12, 2020
Some of the stocks that may grab investor focus today are:
Benzinga · 05/12 09:16
Akebia Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the pricing of an underwritten public offering of 11,000,000 shares of common stock at a public off
PR Newswire · 05/12 01:15
Akebia Therapeutics Announces Proposed $100M Public Offering of Common Stock
Benzinga · 05/11 20:13
Stocks That Hit 52-Week Highs On Monday
Monday's morning session saw 70 companies set new 52-week highs.
Benzinga · 05/11 14:29
How Akebia Therapeutics (AKBA) Stock Stands Out in a Strong Industry
Akebia Therapeutics (AKBA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Zacks · 05/11 12:36
Akebia Therapeutics to Present at RBC Capital Markets Global Healthcare Virtual Conference
PR Newswire · 05/08 13:00